title: 4.5-hour time window for intravenous thrombolysis with recombinant tissue-type plasminogen activator is established firmly.
authors: From the Departments of Neurology and Neurogeriatry, Johannes Wesling Clinic Minden, Minden, Germany (P.D.S.); and Department of Neurology, University Clinic at Erlangen, Germany (M.K.).
authors: Peter D
authors: PD
authors: Schellinger
authors: Martin
authors: M
authors: Köhrmann
mesh_terms: D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017408:Guidelines as Topic; D006801:Humans; D007275:Injections, Intravenous; D020521:Stroke / Q000188:drug therapy*; D059409:Stroke, Lacunar / Q000628:therapy; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator
keywords: controlled clinical trials, randomized; stroke; thrombolytic therapy